Pediatric Nephrotic Syndrome. Nephrotic syndrome
Conditions
Interventions
Intervention 1: Intervention group 1: Levamisole (manufactured by Rooz Daroo Pharmaceutical Co.), daily administration 2.5 mg/kg. Intervention 2: Intervention group 2 : Levamisole (manufactured by Roo
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 15 Years
Inclusion criteria
Inclusion criteria: Patients affliction with steroid-dependent idiopathic nephrotic syndrome or with high number of relapses 2-15 years old non-use of steroid supplementation
Exclusion criteria
Exclusion criteria: Patient treatment with Levamisole for less than 4 months (the minimum follow-up period) the children’s affliction with any chronic disease other than nephrotic syndrome
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of Pediatric Nephrotic Syndrome. Timepoint: 4 Weeks. Method of measurement: Three-plus Proteinuria (measured by a special tape that contains protein indicator; three-plus and higher is considered relapse) on three consecutive days at the end of each month. | — |
Secondary
| Measure | Time frame |
|---|---|
| Dose of corticosteroid. Timepoint: 4 Weeks. Method of measurement: Laboratory results and clinical evaluation.;Drug side effects. Timepoint: 4 Weeks. Method of measurement: Ask the patient or his legal guardian, as well as laboratory results and clinical evaluations. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Shourmij
Kermanshah University of Medical Sciences
Outcome results
None listed